var data={"title":"Collagenase (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Collagenase (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/413070?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=collagenase-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Collagenase (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780518\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Corporal rupture (penile fracture) or other serious penile injury in the treatment of Peyronie disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) collagenase-treated patients in clinical studies. In other collagenase-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile &ldquo;popping&rdquo; sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) collagenase-treated patients.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risks of corporal rupture or other serious penile injury, collagenase is available for the treatment of Peyronie disease only through a restricted program under a risk evaluation and mitigation strategy (REMS) called the Xiaflex REMS program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916615\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xiaflex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45824763\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Xiaflex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916619\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916767\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dupuytren contracture:</b> Intralesional: Inject 0.58 mg per cord affecting a metacarpophalangeal (MP) joint or a proximal interphalangeal (PIP) joint.  If contracture persists, finger extension procedure should be performed 24 to 72 hours following injection to facilitate cord disruption. If MP or PIP contracture remains, may reinject cord with a single dose of 0.58 mg 4 weeks following initial injection; injections and finger extension procedures may be administered up to 3 times per cord separated by ~4 week intervals. <b>Note:</b> Up to 2 injections per hand may be used during a treatment; 2 palpable cords affecting 2 joints or 1 palpable cord affecting 2 joints in the same finger may be injected at 2 locations during a treatment. Other palpable cords with contractures of MP or PIP joints may be injected at other treatment visits ~4 weeks apart.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peyronie disease:</b> Intralesional: Males: Inject 0.58 mg into a Peyronie plaque; repeat injection 1 to 3 days later. A penile modeling procedure should be performed 1 to 3 days after the second injection. Administer a second treatment cycle (two 0.58 mg injections and a penile modeling procedure) in ~6 weeks if needed (maximum, 4 treatment cycles [a total of 8 injection procedures and 4 penile modeling procedures]); subsequent treatment cycles should not be administered if the curvature deformity is &lt;15 degrees after a treatment cycle or health care provider determines further treatment is not indicated. The safety of more than 1 treatment course (ie, 4 treatment cycles) is not known. <b>Note:</b> If more than 1 plaque is present, inject into the plaque causing the curvature deformity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916768\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916769\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916770\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916775\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xiaflex: 0.9 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916617\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916612\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68JQoq8hD2JENqwKfL3e1IAA==&amp;TOPIC_ID=9076\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916771\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inject intralesionally into a palpable cord or plaque using a 1 mL syringe with 0.01 mL graduations with a 27-gauge <sup>1</sup>/<sub>2</sub>-inch needle. If reconstituted solution is refrigerated, warm to room temperature for ~15 to 60 minutes before use. Refer to product labeling for additional administration details. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupuytren contracture: Divide dose into 3 injections; after correct needle placement, inject <sup>1</sup>/<sub>3</sub> of the dose, then reposition the needle in a distal location ~2 to 3 mm from the initial injection for the second injection (<sup>1</sup>/<sub>3</sub> of the dose), followed by the final injection (<sup>1</sup>/<sub>3</sub> of the dose) positioned ~2 to 3 mm proximal to the initial injection. To avoid tendon rupture when injecting a cord affecting a PIP joint of the fifth finger, needle insertion should not be &gt;2 to 3 mm in depth or &gt;4 mm distal to the palmar digital crease. Do not administer local anesthetic agent prior to administration due to possible interference with proper needle placement. When administering two injections in the same hand during a treatment, begin with the affected finger in the most medial aspect of the hand and continue toward the lateral aspect (eg, fifth finger to index finger). When administering two injections in a cord affecting two joints in the same finger, begin with the affected joint in the most proximal aspect of the finger and continue toward the distal aspect (eg, MP to PIP).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peyronie disease: Local anesthetic may be administered prior to injection. The penis should be in a flaccid state before injection. The first injection should be into the plaque at the point of maximum concavity (or focal point) in the bend of the penis; second injection of each treatment cycle should be made ~2 to 3 mm apart from the first injection. Inject only into the plaque; avoid injection into the urethra, nerves, blood vessels, corpora cavernosa, or other collagen-containing structures of the penis to avoid damage to these structures and possible corporal rupture. Do not advance the needle beneath the plaque or perpendicularly towards the corpora cavernosum. Withdraw the needle slowly to deposit the full dose along the needle track within the plaque.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916621\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dupuytren contracture:</b> Treatment of adults with Dupuytren contracture with a palpable cord</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peyronie disease:</b> Treatment of adult men with Peyronie disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916611\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Collagenase clostridium histolyticum (Xiaflex) may be confused with topical collagenase formulation (ie, Santyl)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xiaflex may be confused with Zanaflex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916713\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dupuytren's contracture:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (primarily as swelling of injected hand: 73% to 77%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (4% to 15%), hemorrhagic blister (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (59% to 70%), lymphadenopathy (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&ge;86%; neutralizing antibodies: AUX-I: 10%; AUX-II: 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (6% to 38%), injection site reaction (35%; includes erythema, inflammation, irritation), swelling at injection site (5% to 24%), tenderness at injection site (24%), pain at injection site (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (35% to 51%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Laceration (9% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Lymph node pain (8%), axillary pain (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (6%), ecchymoses (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hematoma at injection site (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, antibody development (IgE; increased with successive injections), causalgia, ligament disorder, pulley rupture, rupture of tendon, sensory disturbance, vasodepressor syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peyronie disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Penile hematoma (66%; severe: 4% to 6%), penile swelling (55%), penile pain (45%), penile ecchymoses (15%), penile popping sensation (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (55% to &gt;99%; neutralizing antibodies: AUX-I: 60%; AUX-II: 52%; no correlation to clinical response or adverse reaction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Procedural pain (2%), suprapubic pain (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hemorrhagic blister (5%), genital pruritus (3%), skin discoloration (2%), localized vesiculation (injection site, 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Blisters on penis (3%), painful erection (3%), erectile dysfunction (2%), dyspareunia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Itching at injection site (1% to 4%), localized edema (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Nodule (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Penile fracture, sudden penile detumescence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916625\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of Peyronie plaques that involve the penile urethra; history of hypersensitivity to collagenase or to collagenase used in any other therapeutic application or application method.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916626\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis, may occur in response to administration of foreign proteins (ie, collagenase). Health care providers should be prepared for the immediate treatment with epinephrine for any possible severe allergic reaction. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Avoid use in patients with coagulation disorders, including patients receiving concomitant anticoagulants (except low-dose aspirin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corporal rupture: Peyronie disease: <b>[U.S. Boxed Warning]: Corporal rupture (penile fracture) was reported in 0.5% of patients in clinical studies; severe penile hematoma and a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile &ldquo;popping&rdquo; sound or sensation was also reported. Signs or symptoms that may reflect serious penile injury should be promptly evaluated.</b> Careful injection technique of collagenase into the Peyronie plaque is required to avoid inadvertent injection into the urethra, nerves, blood vessels, corpora cavernosa, or other collagen-containing structures of the penis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tendon rupture: Dupuytren contracture: Administration may result in tendon rupture, ligament damage, or other serious injury (eg, pulley rupture, sensory and pain abnormalities, and skin lacerations); careful injection technique of collagenase into the Dupuytren cord is required to avoid inadvertent injection into tendons, nerves, blood vessels, or other collagen-containing structures of the hand. Skin laceration requiring skin graft after finger extension procedures has been reported. Signs or symptoms of serious injury to the injected hand or finger should be immediately evaluated; surgical intervention may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: IgE-anti-drug antibodies commonly developed in treated patients, with higher frequencies and titers seen in patients treated with successive injections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Only health care providers skilled in the treatment of Dupuytren contractures or Peyronie disease and appropriate injection procedures should administer treatment. Local anesthetic is not recommended prior to Dupuytren contracture treatment due to possible interference with proper needle placement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: Peyronie disease: [U.S. Boxed Warning]: Because of the risks of corporal rupture or other serious penile injury, collagenase is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program. Prescribers and healthcare sites must be certified with the program. Call 1-877-313-1235 or visit www.Xiaflexrems.com for more information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299090\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10073091\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9076&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916622\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916623\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Pharmacokinetic studies in humans did not show quantifiable systemic levels following intralesional injection into a Dupuytren cord; however, low levels were quantifiable in the plasma following administration into the penile plaque. IgE-anti-drug antibodies commonly develop in treated patients; effects to the fetus are unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099225\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if collagenase is excreted in breast milk. The manufacturer recommends that caution be exercised when administering collagenase to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916773\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Range of motion (Dupuytren contracture); curvature deformity (Peyronie disease).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916724\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Collagenase clostridium histolyticum contains two forms of microbial collagenase (Collagenase AUX-I and Collagenase AUX-II) isolated and purified from the fermentation of <i>Clostridium histolyticum</i> bacteria; collagenase lyses collagen, leading to enzymatic disruption of contracted Dupuytren cord or Peyronie plaque (both comprised primarily of collagen).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9916726\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption: Systemic plasma concentrations of collagenase AUX-I or collagenase AUX-II were undetectable for up to 30 days following intralesional injection into a Dupuytren cord. Low levels of collagenase AUX-I and AUX-II were quantifiable for up to 30 minutes following intralesional injection into a Peyronie plaque.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322818\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Xiaflex Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.9 mg (1): $4,718.35</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992816\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Xiaflex (AU, JP);</li>\n      <li>Xiapex (CH, CY, CZ, DK, EE, ES, FR, GB, HR, HU, IE, IS, LT, LU, LV, MT, NL, NO, PL, SE, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Hurst LC, Badalamente MA, Hentz VR, et al, &ldquo;Injectable Collagenase Clostridium Histolyticum for Dupuytren&rsquo;s Contracture,&rdquo; <i>N Engl J Med</i>, 2009 361(10):968-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/collagenase-systemic-drug-information/abstract-text/19726771/pubmed\" target=\"_blank\" id=\"19726771\">19726771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xiaflex (collagenase clostridium histolyticum) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; July 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9076 Version 105.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F23780518\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9916615\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45824763\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9916619\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9916767\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9916768\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9916769\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9916770\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9916775\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9916617\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9916612\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9916771\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9916621\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9916611\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9916713\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9916625\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9916626\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299090\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F10073091\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9916622\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9916623\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21099225\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9916773\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9916724\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9916726\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322818\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992816\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9076|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=collagenase-systemic-patient-drug-information\" class=\"drug drug_patient\">Collagenase (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}